FAB Stock 50% Margin Pivot Meets Severe Cash Runway
FAB.L stock analysis: margin expanding to 50% signals biotech turnaround — buy or sell? 👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends In this deep dive, we break down Fusion Antibodies plc (FAB.L) and its strategic transition from a traditional fee-for-service model to a high-margin intellectual property partner. With gross margins expanding to 50% in FY2026, the key question for investors is whether its newly commercialized OptiMAL® platform can…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.